CytoDyn (OTCMKTS:CYDY) Stock Crosses Above Two Hundred Day Moving Average – What’s Next?

CytoDyn Inc. (OTCMKTS:CYDY) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.28 and traded as high as $0.28. CytoDyn shares last traded at $0.2681, with a volume of 3,466,348 shares changing hands.

CytoDyn Stock Down 3.3%

The company has a market capitalization of $331.53 million, a P/E ratio of -8.64 and a beta of 1.13. The firm’s 50-day moving average price is $0.26 and its 200 day moving average price is $0.28.

CytoDyn (OTCMKTS:CYDY) last released its quarterly earnings results on Friday, January 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter.

CytoDyn Company Profile

CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.

In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.